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Acute exacerbations of chronic bronchitis (AECB) is an important cause of death and morbidity in developed 
countries and also has significant economic impact. The disease is characterized by increased dyspnoea, sputum 
volume and sputum purulence; the most commonly associated pathogens are Haemophilus inzuenzae, Streptococcus 
pneumoniae and Moraxella catarrhalis. H. injluenzae and S. pneumoniae express virulence determinants that directly 
and indirectly impair mucociliary clearance and incite other consequences that are permissive to microbial persistence. 
Regarding the use of antibiotics, there is currently a lack of large-scale clinical trials that are sufficiently powerful 
to provide good evidence-based information. Nonetheless, antimicrobial chemotherapy has repeatedly been shown 
to confer benefit in patients with moderately severe features of AECB. Simple clinical criteria can be used to identify 
patients in whom there is a higher likelihood of treatment failure or mortality during AECB. These include 
significant cardiopulmonary co-morbidity, frequent exacerbations, advanced decline in lung function, malnutrition 
or other generalized debility, advanced age (> 70 years) and concurrent treatment with corticosteroids. In such 
patients, an aggressive antimicrobial approach to AECB may be warranted in order to prevent clinical failure or re- 
presentation. From a clinical perspective, appropriate drugs include those that are stable to b-lactamases, are 
bactericidal against causative pathogens, penetrate diseased lung tissue in high concentrations and have a good 
safety profile. 
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Introduction 
Chronic obstructive pulmonary disease (COPD) is char- 
acterized by irreversible airflow obstruction due to chronic 
bronchitis or emphysema; this is defined as a ratio of forced 
expiratory volume in 1 set: forced vital capacity (FEVI: 
FVC) of less than 70%. Patients are subject to acute 
exacerbations in which there is an acute decline in FEV,, 
often in association with increased dyspnoea, and produc- 
tion of increased quantities of sputum which may be 
purulent. Recent epidemiological data from the U.S.A. 
show that COPD affects an estimated 50 million individuals 
and is the fifth most common cause of death (1). 
Development of respiratory failure during an acute exacer- 
bation of COPD occurs in those whose stable airway 
function is severely impaired (2). However, respiratory 
failure is not the only cause of death in this group; as acute 
exacerbation of COPD can also result in death due to other 
causes, such as acute myocardial infarction (3). 
The role of infection in AECB is a contentious issue. 
Bacteria and neutrophils are frequently identified in the 
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sputum of patients with AECB, but it is unclear whether 
they have a causal relationship with the development of 
exacerbations, or whether bacterial counts are merely 
allowed to increase as a result of the acute impairment of 
mucociliary clearance. Studies with antibiotics have re- 
vealed a positive, but small effect compared to placebo, in 
patients with AECB. In the interests of targeting therapy to 
those who need it most, there are some data that allow us to 
identify patients who do not benefit from antimicrobial 
therapy, and others for whom it is probably a mandatory 
component of management. 
Role of infection in AECB 
Within the trachea, bronchi and medium to small airways 
of the lung, the respiratory mucosa is normally sterile. 
During the evolution of COPD in an individual patient, 
there is a gradual increase in mucus production, depressed 
ciliary function and epithelial cell injury. Bacteria that are 
not normally present in the airway below the larynx are 
then able to colonize the diseased epithelium (4). The 
association of purulent sputum in chronic bronchitis with 
Haemophilus influenzae and Streptococcus pneumoniae was 
convincingly demonstrated by May (5). These pathogens, 
of course, are common colonizers of the upper respiratory 
tract and they can be recovered from the lower airways even 
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during stable COPD (6). Monso et al. (7) performed 
bronchoscopic sampling by protected specimen brush 
(PSB) of the lower airways of outpatients with stable 
COPD and compared this with patients with acute 
exacerbations of COPD. This showed that the prevalence 
of lower airway bacterial colonization in outpatients with 
stable COPD is high (25%), mainly due to H. infruenzae in 
S. pneumoniae, whilst exacerbated COPD is associated with 
a higher yield (51.7%) of these pathogens and higher 
numbers of organisms. In patients with more severe AECB, 
PSB will retrieve a wider range of bacteria including Gram- 
negative enteric bacilli, Pseudomonas sp. and Stenotropho- 
monas sp. (8). Therefore at the very least, even if infection 
with bacterial pathogens is not the cause of acute 
exacerbations, they are clearly flourishing in the lower 
airways in some of these patients, in association with an 
inflammatory infiltrate (as evidenced by a yield of 
neutrophils in sputum). Molecular typing of strains of H. 
influenzae isolated from sputum of patients with COPD has 
demonstrated that a single strain may persist for many 
months within the lower respiratory tract mucosa of these 
patients, and remains present even if there have been acute 
exacerbations of COPD which have been treated with 
antibiotics (9). This suggests that Haemophilus infuenzae 
exists in a state of equilibrium with the host defences, which 
is lost during exacerbations. During antimicrobial therapy, 
the equilibrium is restored though the microbe is not 
eradicated. During chronic colonization there is likely to be 
a constant balancing act between the host and its bacterial 
colonizers. On the one hand, host defences include cough, 
ciliary beating, mucus containing secreted immunoglobulin 
and lactoferrin, and alveolar macrophages. On the other 
hand, microbes have adapted to avoid rapid clearance, gain 
nutrients and survive in the respiratory tract sufficiently to 
grow and disseminate to other hosts. In the case of 
Haemophilus injluenzae, the factors which enable the 
organism to achieve these aims include the production of 
a polysaccharide capsule, pili, lipopolysaccharide, outer 
membrane proteins, iron-regulated proteins and factors 
toxic to ciliary activity (reviewed by Read and Finch) (10). 
The pathogens associated with exacerbations of COPD 
have been summarized by Ball (11) (Table 1). Although 
TABLE 1. Pathogens associated with exacerbations of 
chronic bronchitis 
Bacteria Viruses 
H. influenzae Influenza/parainfluenza 
viruses 
S. pneumoniae Respiratory syncytial virus 
M. catarrhalis Rhinoviruses 
Coronaviruses 
Staphylococcus aureus 
Pseudomonas aeruginosa 
Enteric Gram-negative bacilli 
Mycoplasma pneumoniae 
there is clear evidence of an increase in bacterial load in 
some patients with AECB, this is not always the case. 
Fagon et al. (12) performed bronchoscopy with retrieval of 
organisms by protected specimen brush on 54 patients 
receiving mechanical ventilation during AECB with hyper- 
capnic respiratory failure. Bacteria (predominantly H. 
influenzae and S. pneumoniae) were present in 50% of 
patients. In the remaining patients, the PSB samples were 
sterile. No difference was observed in clinical presentation, 
severity or mortality between the patients infected with 
bacteria and those not. In at least 30% of AECB, there is 
evidence of viral infection either by influenza virus, 
respiratory syncytial virus (RSV) or rhinovirus, detected 
either by direct culture or serology (13). 
In summary, bacteria are present within the lower 
airways in most patients with stable COPD. In most cases 
of AECB, there is evidence of increased inflammation in the 
lower airways together with an increase in bacterial 
numbers. Whether the latter is cause or effect has not been 
elucidated. 
Antibiotic therapy in COPD 
The corps of studies of antibiotic efficacy in bronchitis have 
been reviewed by Saint et al. (14) and Orr et al. (15). The 
review of Saint et al. is summarized in Table 2. The studies 
assessed in this meta-analysis differed in terms of the main 
outcomes measured (symptom score, days of illness, etc.) 
so it was able only to report a crude overall effect size 
relative to placebo, and the effect on peak expiratory flow 
(PEF), which was reported in the majority of the studies. 
Overall, the meta-analysis demonstrated a modest but 
statistically significant benefit from antibiotic therapy 
(overall effect size 0.22 compared with placebo, 95% CI: 
0.10-0.34). The peak expiratory flow improved by a small 
amount (10.75 1 min-’ compared with placebo). None of 
the studies assessed included any quality of life outcomes. 
The largest of the studies assessed, by Anthonisen et al. 
(23), stratified patients according to the severity of their 
illness and was able to demonstrate the largest effect size in 
those patients with the most severe exacerbations. Anti- 
biotics gave the greatest benefit in terms of resolution of 
symptoms and avoidance of deterioration, in those patients 
who had two or more of the following features, increased 
dyspnoea, increased sputum volume and increased sputum 
purulence. 
In Europe, the commonest antimicrobials used in AECB 
include the aminopencillins (U.K. and France), the macro- 
lides (Spain), tetracyclines (Germany) and third generation 
cephalosporins (Italy) (25). Both the European Respiratory 
Society (26) and the American Thoracic Society (27) have 
produced guidelines for the management of COPD. These 
endorse the judicious use of simple and inexpensive 
antimicrobial therapy based on individual clinical assess- 
ment by physicians. The British Thoracic Society has 
recommended antibiotic therapy if any two of worsening 
dyspnoea, increased sputum volume or increased sputum 
purulence are present (28). 
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TABLE 2. 
Source, y Setting No. of 
subjects 
Antibiotic 
regimen 
Main outcome 
measure(s)+ 
Effect 
sizet 
Elmes et al. (16) 1957 Outpatient 113* 
Berry et al. (17) 1960 Outpatient 33 
Fear and Edwards (18) 1962 Outpatient 119* 
Elmes et al. (19) 1965 Inpatient 56 
Petersen et al. (20) 1967 Inpatient 19 
Pines et al. (21) 1972 Inpatient 149 
Nicotra et al. (22) 1982 Inpatient 40 
Anthonisen et al. (23) 1987 Outpatient 310* 
Jorgensen et al. (24) 1992 Outpatient 262 
Oxytetracycline 
Oxytetracycline 
Oxytetracycline 
Ampicillin 
Chloramphenicol 
Tetracycline 
Tetracycline 
Combination of 
sulfamethosazole 
and trimethoprim, 
amoxicillin, or 
doxycycline 
Amoxicillin 
Days of illness 
Overall symptom 
score 
Overall score by 
physician 
Change in PEFR 
Change in PEFR 
Overall score by 
physician/change in 
PEFR 
Final PaO&hange 
in PEFR 
Days of illness/ 
change in PEFR 
Overall score by 
physician/change in 
PEFR 
0.30 
0.71 
0.31 
0.49 
- 0.04 
0.39 
0.23 
0.38 
- 0.09 
*Studies in which the unit of analysis is number of exacerbations; in other studies, the unit of analysis is the number of 
patients. 
+PEFR indicates peak expiratory flow rate; $Effect size is the difference between the mean outcome in the antibiotic and 
placebo groups divided by the pooled SD. 
Table reproduced from (14). 
Antimicrobial resistance amongst 
pathogens implicated in AECB 
The major pathogen, Haemophilus inJEuenzae, is demon- 
strating rising resistance to the aminopenicillins which is 
mainly due to production of p-lactamases. In the U.K., 
prevalence of resistant H. infuenzae ranges from 424% 
(29). Both of the major /?-lactamases are plasmid-mediated 
and transferable, and so their prevalence is expected to rise 
with increased use of aminopenicillins in the community. 
Erythromycin has virtually no activity against Haemophilus 
injluenzae, but clarithromycin has better activity, though 
this is based on a study which demonstrated that 96% of H. 
influenzae isolates had a MIC of 8 pg ml-’ or less (29). 
Azithromycin has better in vitro activity than the other 
macrolides (20). Moraxella catarrhalis demonstrates almost 
universal production of p-lactamases and is also resistant to 
trimethoprim (reviewed by Amyes and Gemmell) (31). 
Resistance to p-lactams amongst Streptococcus pneumoniae 
isolates is due to a stepwise mutation of the penicillin- 
binding proteins. There is controversy regarding the impact 
of penicillin resistance of pneumococci on the management 
of patients with respiratory tract infection. Patients with 
pneumonia treated with high dose penicillin and subse- 
quently shown to be infected with penicillin-resistant 
pneumococci, showed no increase in severity of outcome 
compared to patients with sensitive strains (32). However, 
the effect of penicillin resistance amongst pneumococci on 
outcomes in community-treated AECB, where lower doses 
of oral agents are generally used, has not been investigated. 
Pneumococcal resistance is associated with childcare 
facilities, hospital facilities, antibiotic use and immunocom- 
promise (33). Importantly, long-term treatment with low 
doses of p-lactam antibiotics has recently been shown to 
contribute to the selective pressure promoting pharyngeal 
carriage of penicillin-resistant strains of S. pneumoniue (34). 
The potential implications of this for patients with AECB 
treated in the community are obvious. 
Identifying those patients most likely 
to benefit from antibiotic therapy 
With regard to patients presenting to their general 
practitioner with cough, it is possible to identify patients 
for whom no benefit will accrue from the use of antibiotics. 
These include patients with acute bronchitis and otherwise 
good respiratory health (15,35). A recent meta-analysis of 
double-blind placebo-controlled trials of antibiotics in 
patients presenting with acute cough demonstrated that 
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neither resolution of cough nor clinical improvement was 
significantly hastened by antibiotic therapy (36). 
Regarding patients with COPD, the trial of Anthonisen 
et al. (23) showed that patients with more than two of (i) 
increased dyspnoea, (ii) increased sputum volume and (iii) 
increased sputum purulence can benefit from antibiotic 
therapy, whilst those patients with only one of these 
features are unlikely to benefit. With such a heterogeneous 
population, it is possible that positive benefit from 
antibiotics in the more severe subgroups has been diluted 
out in the studies of antibiotic therapy in patients with 
AECB. The majority of patients presenting to their 
community physician with AECB do not fulfil these simple 
clinical criteria and are therefore unlikely to benefit from 
antimicrobial therapy. 
There is a strong case for targeting antibiotic therapy in 
patients with more severe manifestations of AECB. The 
major determinants of the survival over the long-term in 
patients with AECB are age and the degree of airways 
obstruction (FEVi < 50%) (37). Co-existing cardiopulmon- 
ary disease such as ischaemic heart disease, and also 
diabetes, have been linked to poor outcome in COPD 
patients (38). Use of oral corticosteroids has also been 
linked to poor outcome (39). Seneff et al. (40) demonstrated 
that amongst patients admitted to intensive care units with 
AECB, variables associated with hospital mortality in- 
cluded age, severity of respiratory and non-respiratory 
organ system dysfunction, and hospital length of stay 
before intensive care unit (ICU) admission. These factors 
imply a worse prognosis of an infective AECB. 
Although each of these factors is associated with a poorer 
outcome of COPD, their effects are not necessarily 
mediated through infection. Prescott et al. (41) investigated 
patients who had died from an AECB and determined 
whether their death was directly linked to infection on 
clinical grounds. The only historical risk factor that was 
associated with an infective ‘death’ was the presence of 
chronic mucus hypersecretion. Despite this reservation, a 
strong argument to target therapy at those patients with 
manifestations of disease associated with a poor prognosis 
can be made. Future studies should determine whether use 
of antimicrobial therapy in these patients affects clinical 
outcome, quality of life measurements and the likelihood of 
hospital admission. Of further importance, economically, 
and in terms of quality of life, is the failure of outpatient 
management resulting in patients needing to return to their 
physician. One study has determined that these patients can 
be identified. Those with co-existing cardiopulmonary 
disease, or who have a history of recurrent exacerbations 
(> 3 per year) are at greatest risk of failing therapy and 
needing a return visit (42). 
Appropriate antimicrobial therapy in 
patients with AECB 
Table 3 suggests appropriate antimicrobial therapy in 
patients with AECB. The majority of patients presenting 
to their general practitioner will not require antibiotic 
therapy. These are patients with acute bronchitis and simple 
chronic bronchitis with reasonable lung function and less 
than two of the three of the ‘Anthonisen criteria’. Patients 
who are ambulant and relatively well with no co-existing 
illnesses, but who present with two or more ‘Anthonisen 
criteria’ can probably be managed by simple therapy with 
,&lactams, for example an aminopenicillin, which is cheap 
and likely to be efficacious in this group. However, local 
TABLE 3. Rationing of antibiotic therapy in cough and AECB 
Simple antibiotic therapy 
(e.g. aminopenicillins) 
Sophisticated antibiotic 
therapy (e.g. co-amoxiclav, 
quinolone, modern 
macrolides) 
Antimicrobial use Clinical presentation Other considerations 
None Acute bronchitis 
AECB but <2 of 
T sputum volume, 
t sputum purulence of 
T dyspnoea 
AECB with 12 of 
t sputum volume, 
T sputum purulence or 
t dyspnoea 
Patients who are relatively 
young, with infrequent 
exacerbations and no significant 
comorbidities 
AECB with >2 of 
t sputum volume, 
t sputum purulence or 
fdyspnoea AND severe COPD (FEVr 
FVC < 50%) OR elderly OR 
comorbid conditions OR 
concurrent oral corticosteroid use 
Especially in facilities or areas 
with high rates of /I-lactamase- 
secreting H. influenzae or 
penicillin-resistant pneumococci 
Patients with frequent exacerbations 
are theoretically more likely to be 
infected with resistant organisms 
ACUTE EXACERBATIONS OF CHRONIC BRONCHITIS 849 
microbiology data may point to a high prevalence of fi- 
lactamase-secreting H. injkenzae, in which case therapy 
with antibiotics that are stable to p-lactamase is logical. 
These include co-amoxiclav, the quinolones and modern 
macrolides (clarithromycin or azithromycin). In patients 
with advanced age, or with cardiopulmonary comorbidities 
or moderately to severely impaired lung function (FEVi 
<50%), it would seem logical to treat infection with more 
sophisticated antibiotics in order to ensure microbiological 
clearance. Particularly in those patients with recurrent 
exacerbations, infection with a p-lactamase-secreting H. 
inJIuenzae is more likely. In addition, these patients are 
more likely to be infected with unusual pathogens such as 
the Gram-negatives such as Enterobacteriaceae and Sta- 
phylococcus aureus. In these patients the use of advanced 
antimicrobials such as co-amoxiclav, quinolones and 
modern macrolides would seem logical. This has no current 
evidence basis, and trials to determine whether they have an 
effect on clinical outcome should be conducted, though 
some have argued that this will be difficult (43). 
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